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Background. The magnitude of the 2013–2016 Ebola virus disease outbreak in West Africa was unprecedented, with >28 500
reported cases and >11 000 deaths. Understanding the key elements of Ebola virus transmission is necessary to implement adequate
infection prevention and control measures to protect healthcare workers and halt transmission in the community.
Methods. We performed an extensive PubMed literature review encompassing the period from discovery of Ebola virus, in 1976,
until 1 June 2016 to evaluate the evidence on modes of Ebola virus shedding and transmission.
Findings. Ebola virus has been isolated by cell culture from blood, saliva, urine, aqueous humor, semen, and breast milk
from infected or convalescent patients. Ebola virus RNA has been noted in the following body fluids days or months after onset
of illness: saliva (22 days), conjunctiva/tears (28 days), stool (29 days), vaginal fluid (33 days), sweat (44 days), urine (64 days), am-
niotic fluid (38 days), aqueous humor (101 days), cerebrospinal fluid (9 months), breast milk (16 months [preliminary data]), and
semen (18 months). Nevertheless, the only documented cases of secondary transmission from recovered patients have been through
sexual transmission. We did not find strong evidence supporting respiratory or fomite-associated transmission.
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Ebola virus is a 19-kb, single-strand, negative-sense RNA virus
that belongs to the family Filoviridae, order Mononegavirales.
Among the 5 species of the genus, 4 are known to cause Ebola
virus disease (EVD) in humans: Zaire ebolavirus (EBOV),
Sudan ebolavirus (SUDV), Bundibugyo ebolavirus, and Taï Forest
ebolavirus. Reston ebolavirus seems to cause only asymptomatic
infection in humans [1]. The main reservoir for this virus genus
is considered to be bats [2]. Viral entry into humans is thought
to occur at mucosal surfaces or through breached skin [3]. Ebola
viruses primarily target dendritic cells, monocytes, and macro-
phages before reaching the lymph nodes and eventually the ge-
neral circulation through the lymphatics, after which they infect
and replicate in a wide range cells and organs, especially the
liver, spleen, and adrenal glands [3]. The combined viral cyto-
pathic effect and the host response result in a strong and poten-
tially deleterious inflammatory reaction that can lead to severe
coagulopathy, shock, and fatal end organ damage [4]. Outside
the body, Ebola virus has been shown to survive up to 3 days
on a Tyvek coverall in conditions reproducing a tropical climate
[5], up to 8 days in wastewater [6], and up to 46 days in blood-
based liquid media at room temperature [7].
As of March 2016, >28 500 symptomatic cases and >11 000
deaths attributed to EVD have been reported during the
2013–2016 outbreak in West Africa [8]. Nearly 900 healthcare
workers (HCWs) working on the frontlines of the outbreak has
contracted EVD, with 513 deaths [8, 9]. Twenty-seven patients
with EVD, mostly working for humanitarian aid agencies, have
been medically evacuated and treated in the United States or
Europe [10] since the beginning of the 2013–2016 outbreak,
leading to 3 cases of nosocomial transmission [11, 12].Accumu-
lating evidence from the massive outbreak in West Africa dem-
onstrate EBOV persistence in various immune-privileged sites
after recovery from acute disease, with the potential for reacti-
vation of replication, virus shedding, and secondary transmis-
sion [13, 14], especially sexual transmission from persistent
virus in male survivors [15, 16]. A thorough understanding of
the dynamics of Ebola virus persistence and shedding in the di-
verse body compartments and fluids is essential to estimating
and mitigating risk of transmission from EVD survivors. We re-
view here the present evidence on the subject and discuss the
potential risk of transmission from persistent Ebola virus
infection.
METHODS
We performed a comprehensive PubMed literature review en-
compassing the period from discovery of Ebola virus, in 1976,
until 1 June 2016, using the search terms “Ebolavirus”, “Ebola
virus disease”, “transmission”, and “shedding” in various com-
binations without any language restrictions. Articles were in-
cluded if considered relevant to the review.
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SHEDDING
The Need for Standardization
In patients with acute EVD, there is evidence that the virus is
shed in a broad range of body compartments and fluids, includ-
ing blood, stool, urine, sweat, vaginal secretions, amniotic fluid,
saliva, tears, aqueous humor, cerebrospinal fluid (CSF), breast
milk, and semen [3, 17–20]. The preponderance of the data
come from RNA detection assays, primarily real-time reverse
transcription–polymerase chain reaction (rRT-PCR), which ap-
pears to presently be the most sensitive diagnostic tool available.
Data are derived from testing of convenience samples, with the
largest data collection on RNA shedding in humans coming
from the 2013–2016 epidemic in West Africa. Most recent in-
vestigations have not included confirmatory cell culture to dem-
onstrate the presence of infectious virus, making interpretation
of infectivity difficult, since nucleic acid detection may simply
reflect the presence of remnant viral RNA or even defective in-
fectious particles [21]. Furthermore, no standardized assay or
international units exist to allow reliable comparison of viral
loads between rRT-PCR assays. Although the Makona variant
of EBOV that caused the outbreak in West Africa is genetically
similar to EBOV variants from Central Africa, functional or
“phenotypic” data are lacking to assess whether different vari-
ants or species may have different dynamics of virus persistence
and shedding. Factors that may influence results from cell cul-
ture include the size of the inoculum, the type of specimen, and
the cell line used.
Blood
Soon after initial dissemination to and infection of the organs,
explosive replication of Ebola virus in the liver, spleen, and ad-
renal glands results in an exponential rise in viral titers in blood
[3] (Figure 1). Blood is among the most infectious body fluids
because of its high viral load. Viral RNA has been detected as
early as 3 days before appearance of fever, in a pregnant
woman [22], and viral load in blood has been described as
high as 107 RNA copies/mL as early as day 2 of disease [23–25].
The peak viremia level is higher and occurs an average of 2 days
later in patients who die, compared with the level in survivors, with
high viral loadmaintained until death [25,26]. In patients who sur-
vive, the viral load in plasma usually starts to decrease 5 days after
symptoms onset [25].
Body Fluids
Evidence from the West African and prior outbreaks suggests
that virus persists in various body compartments and fluids
in addition to blood (Table 1). The viral RNA load in stool
has been found to peak at high levels during the course of the
disease [23, 27]. Studies in nonhuman primates (NHPs) suggest
that the clinical course following infection with the Makona
variant differs from that seen with previous isolated EBOV var-
iants, with Makona being associated with more-frequent diar-
rhea and delayed disease progression [28, 29]. If extrapolatable
to humans, these features may lead to increased transmission
opportunities through the prolonged shedding of infectious
virus, perhaps explaining the high incidence of EVD in West
Figure 1. Evolution of viral load in blood and appearance of immune response during the course of Ebola virus disease (EVD). Abbreviations: IgG, immunoglobulin G;
IgM, immunoglobulin M; RT-PCR, reverse transcription–polymerase chain reaction.
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Africa. While viral RNA has been found in stool after clearance
of viremia, attempts in prior outbreaks to recover virus from
stool in cell culture have failed to date, although this may also
simply reflect the usual technical challenges of bacterial and
fungal overgrowth when attempting to isolate virus from stool
[17, 18].
In a patient requiring mechanical ventilation, a high number
of viral RNA copies were found in bronchoalveolar lavage
20 days after onset of disease [30], suggesting viral replication
in the lungs. It was not specified whether the virus could be iso-
lated in cell culture.
Ebola virus has been cultured from saliva, urine, aqueous
humor of the eye, semen, and breast milk from infected or con-
valescent patients [17, 18, 31, 32].While EBOV RNA and viable
virus are typically detected in saliva early in the course of dis-
ease, viral shedding does not seem to persist after resolution of
symptoms [18,23, 33].From urine specimens, EBOV was isolated
up to 9 days after clearance of viral RNA from blood in a male
patient with severe disease [31], and RNA was recovered up to
36 days (64 days after disease onset) after blood tested negative
by RT-PCR from a young woman who presented with EVD
complicated by severe encephalopathy [34]. In a severely ill pa-
tient who needed renal replacement therapy, EBOV could not
be detected in effluent waste [35]. In breast milk from a lactating
woman, infectious Ebola virus was recovered by cell culture
both during the acute and convalescent phases of disease up
to day 15 after onset of symptoms [18]. Detection of viral
RNA up to 16 months after disease onset has been described,
although at low levels, making interpretation difficult [20].
EBOV has been isolated in aqueous humor from a patient pre-
senting with uveitis up to 14 weeks after onset of disease, 9
weeks after clearance of viremia [32].The maximal reported du-
ration of virus shedding detected in a conjunctival swab in hu-
mans is 10 days after clearance of viremia [33].
Virus has been detected by RT-PCR in semen up to 16
months (488 days) after symptom onset [36] and isolated in
cell culture up to 82 days after symptom onset [17]. EBOV
RNA was detected in semen from half of participants at least
once during follow-up in a pilot study involving 93 EVD survi-
vors in Sierra Leone, with 26% of survivors still shedding viral
RNA 7–9 months after acute disease [13]. The viral load in
semen decreased over time in patients who underwent serial
testing [13, 37, 38]. Whether virus can be cultured that long
after remission remains to be determined. Sexual transmission
during the ongoing EVD outbreak is now quite well document-
ed [15, 16] and has likely been the cause of sporadic EVD resur-
gence in West Africa in late 2015 and early 2016 [39].
Viral RNA has been detected in amniotic fluid 34 days after
clearance of viremia [40], but no attempts at cell culture of this
sample have been published to date. A pregnant survivor deliv-
ered an EVD-positive stillborn baby 32 days after she tested
negative for EBOV [40]. EBOV RNA has been detected in a
skin swab up to 23 days after clearance of viremia [31], but re-
sults of cell culture performed at the same time were negative.
The maximal reported duration of EBOV RNA detection in an
axillary swab was 44 days after onset of symptoms, in a patient
who experienced a prolonged course of disease [34]. Whether
this reflects the presence of infectious virus, remnant RNA, or ex-
ternal contamination from other body fluids remains unknown.
EBOV RNA was detected in CSF 7 days after onset of symp-
toms in a patient who presented with acute encephalopathy [19]
and up to day 41 days (13 days after blood tested negative) in a
patient who experienced a biphasic course of disease character-
ized by the development of encephalitis after a period of im-
provement [34]. Recently, viral RNA and infectious virus were
detected in CSF from an EVD survivor with recrudescent me-
ningoencephalitis 9 months after resolution of disease [41].
The infectivity of the virus identified in the different body flu-
ids during acute EVD requires further evaluation. For example,
we found only 1 attempt in the literature—which failed—to re-
cover virus from a sample of human vomitus [18]. Ebola virus is
known to be inactivated by acidic pH [42], bringing into ques-
tion whether the virus can survive in the gastric environment.
Ebola virus may well reach the intestine by means of viremia. Its
passage into the intestinal lumen may be facilitated by increased
capillary permeability in the mucosa, as suggested by the pres-
ence of viral antigens in mononuclear cells within the lamina
propria of the enteric mucosa in autopsies of deceased patients
with EVD [43].While it is very plausible that large quantities of
Table 1. Maximum Interval Between Onset of Ebola Virus Disease (EVD)
and Last Detection of Ebolavirus RNA by Reverse Transcription–
Polymerase Chain Reaction (RT-PCR) and Last Detection of Ebolavirus by
Culture, by Human Body Fluid Specimen
Specimen(s)
Last Positive RT-PCR
Result, d
Last Positive Culture
Result, d
Saliva 22 4
Tears/conjunctival swab 28 . . .a
Rectal swab/stool 29 . . .b
Vaginal swab 33 . . .c
Amniotic fluid/placenta 38 NA
Skin swab/sweat 44 NA
Urine 64 26
Aqueous humor 101 101
Cerebrospinal fluid 283 NA
Breast milk 486d 15
Semen 488 82
Abbreviation: NA, no report available in the literature.
a No data on final positive results are available. Culture results were negative 6 days after EVD
onset.
b No data on final positive results are available. Culture results were negative 4–12 days after
EVD onset.
c No data on final positive results are available. Culture results were negative 22, 25, and
33 days after EVD onset.
d The time was specified as 16 months in the literature but is converted here to days for
parallelism with units specified elsewhere in the column. This sample was Ebolavirus
RNA positive at low levels, making interpretation difficult. Further testing is necessary to
confirm these results.
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viable Ebola virus are present in stool, Ebola virus stool culture
data are missing. Moreover, there is only one mention of RT-
PCR of intra-articular fluid, results of which were negative [34].
TRANSMISSION
Fruit bats of the Pteropodidae family are considered as the most
likely natural reservoir of Ebola virus [44], and humans can be-
come infected by close contact or by manipulating contaminat-
ed wildlife. Ebola virus is then transmitted from human to
human via direct contact with body fluids of an infected person
or, potentially, from contaminated surfaces and materials.
In animal models, Ebola virus transmission has been demon-
strated through direct virus inoculation in mucosa (via the oral or
conjunctival route); subcutaneous, intraperitoneal, or intramus-
cular injection; and via the respiratory tract, through respiratory
droplets and aerosols. Small viral inocula of <1 plaque-forming
unit can be infectious [45]. Inoculation of the conjunctiva or oro-
pharyngeal mucosa, as well as transcutaneous infection via tiny
skin breaches, are considered the main routes of natural trans-
mission in humans.
Contact With Body Fluids and Cadavers
The major risk for human-to-human transmission is direct
contact with infected body fluids from symptomatic patients
with EVD [46–53]. The mean household secondary attack
rate for individuals with direct contact during previous out-
breaks has been calculated to be 22.9% (95% confidence interval
[CI], 11.6%–34.2%) [54]. Patients often have severe diarrhea
and vomiting, sometimes with bleeding in the late stages, in-
creasing the risk of contact with infectious body fluids. Viral
load increases with disease severity, and the highest levels of
virus are found around the time of death [24–26, 55]. Cadavers
are thus a potent source of infectious virus at high concentra-
tion and must be handled with the same precautions as body
fluids. In carcasses of NHPs experimentally infected by EBOV
and stored in conditions reproducing tropical climates, viral
RNA was detectable for up to 10 weeks after death in oral,
nasal, urogenital, rectal, conjunctival, skin, and blood swab and
various tissue samples; infectious virus could be isolated up to
9 days after death in blood specimens, 7 days in oral swabs,
and 2 to 4 days for other body fluids and tissue samples [27].
Touching dead bodies doubled the risk of infection (risk ratio,
2.1; 95% CI, 1.1–4.2) in household members who had direct
physical contact with a patient with EVD during illness [47].
Only a few EVD cases after needle sticks have been reported
[46, 53, 56–65].However, parenteral inoculation is clearly estab-
lished as a potent means of transmission and was associated
with a shorter incubation period (6.3 days vs 9.5 days) and a
higher overall mortality level (100% vs 88%) during the initial
outbreak of EVD, in Yambuku during 1976 [66]. Recently,
some HCWs with sharps exposures have been treated with post-
exposure prophylactic administration of rVSV-ZEBOV vaccine
[61, 62, 65], monoclonal antibodies and/or favipiravir [64], and
TKM-100802 [65]; none of the reported cases developed EVD,
and no sign of EBOV viremia was detectable, but it is not pos-
sible to know whether infection actually occurred.
HCWs are particularly vulnerable to nosocomial infection,
with associated high mortality rates, probably reflecting high
viral inocula. This is dramatically illustrated by the death of
10% of Sierra Leone HCWs during the early phase of the
West Africa outbreak [53, 67].
EVD as a Sexually Transmitted Disease
Asymptomatic sexual transmission was suspected in a spouse of
a convalescent patient with EVD after the 1995 Kikwit EBOV
outbreak in the Democratic Republic of the Congo [68]. The
most convincing evidence of EVD sexual transmission comes
from the West Africa EBOV epidemic, in which a woman be-
came infected 30 days after the last reported case in Liberia.
Her only identified risk factor was sexual contact with a survivor
who was shedding EBOV RNA in his semen, with a sequence
match with the virus obtained from the blood of the infected
woman [15, 16]. Moreover, none of the mutations found in
the seminal isolate sequence were observed in 22 isolates from
systematic analyses conducted since January 2015 in Liberia. As
a result, new recommendations have been formulated concern-
ing sexual behaviors of EVD survivors, including avoidance of
contact with semen for at least 12 months or until the semen has
twice tested negative for EBOV RNA [20]. However, sexual
transmissions from survivors seem rare and only anecdotally re-
ported, despite the fact that up to 26% of the male survivors may
still shed EBOV RNA in their semen 7–9 months after resolu-
tion of acute illness [13]. EBOV does not survive in acidic envi-
ronments [42], and the acidic pH of normal vaginal mucosa
may act as a natural barrier. The minimal inoculum, and wheth-
er the different phases of the menstrual cycle or concomitant
sexually transmitted diseases can facilitate sexual transmission
remain to be determined.
Although viral RNA has been detected in the convalescent
phase in vaginal fluid of a survivor [18], no female-to-male sex-
ual transmission has been documented to date.
Mother-to-Child Transmission
We found no reports of any attempt to culture virus from am-
niotic fluid. However, the detection of high levels of viral RNA
in amniotic fluid from pregnant women with EVD and on the
placenta and fetus just after delivery [69–71], combined with ex-
tremely high in utero fetal and neonatal mortality rates, strongly
suggest Ebola virus vertical transmission.
Transmission through breastfeeding, even if highly suspected,
has never been formally confirmed [39, 72]. By use of next-
generation sequencing, a case of transmission through breast-
feeding from an asymptomatic mother, whose plasma tested
negative and breast milk tested positive, to her 13-month-old
baby has been described [39].However, other modes of contam-
ination could not be excluded. In a small cohort in Sierra Leone,
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the risk of infection in children was higher if their mother died
of EVD, but it did not seem to be increased by breastfeeding
[73]. As a precaution and because of confirmed isolation of
virus from breast milk [18], current recommendations are for
mothers with EVD to refrain from breastfeeding [74]. EVD sur-
vivors who are lactating should stop breastfeeding only if their
breast milk has been tested positive until 2 negative results are
obtained 48 hours apart, according to World Health Organiza-
tion recommendations [20].
Droplet and Airborne Transmission
There has been much discussion about the potential for air-
borne transmission of Ebola virus because of the implications
for infection control measures [75, 76]. Animal experiments,
including those involving NHPs, have raised concerns about
the possibility of Ebola virus transmission through aerosol or
droplets, resulting in the development of interstitial pneumonia
[77–85]. EBOV inclusions have been demonstrated within mac-
rophages in lungs and free particles within alveolar spaces, fur-
ther supporting the possibility of this route of transmission
[43]. A high viral load has been detected in bronchoalveolar la-
vage of a patient presenting with interstitial pneumonia during
the acute phase of the disease [30]. Experimentally, the EBOV
half-life in aerosol has been calculated to be 15 minutes, with a
decay rate of 3.06% per minute. In other words, at 50%–55%
relative humidity and at a temperature of 19°C–24°C, it takes
104 minutes for 99% of aerosolized EBOV to disappear [7].
EBOV RNA could not be detected in open tubes placed inside
isolation wards for up to 24 hours, arguing against airborne dis-
semination [18] (Kaiser, unpublished data). On the other hand,
EBOV RNA has been found on the outer surface of N95 masks
in Western Africa that were not visibly soiled [75];whether this re-
flects infectious virus and aerosol or droplets versus contamination
from hands touching the mask remains unclear. In prior out-
breaks, infection prevention and control measures using surgical
masks that protect against direct contamination of the oral mucosa
but not aerosol transmission appeared sufficient to prevent noso-
comial transmission [48, 66, 86, 87].While theoretically possible,
epidemiological data do not support airborne transmission as a
mode of human-to-human EVD transmission [47, 50, 51].
However, aerosol-generating medical procedures, such as endo-
tracheal intubation, may pose an enhanced risk, necessitating
appropriate respiratory protection against aerosol spread.
Transmission via Fomites
Transmission via fomites is plausible, given the evidence of vi-
able virus on soiled surfaces and liquids for several days to sev-
eral weeks [5, 7, 18, 88–91]. Three retrospective studies assessed
the risk of contracting EVD among household contacts not hav-
ing direct contact with a primary case [47, 50, 51]; only 1 patient
reported no direct contact and presumably became ill after
sleeping with a blanket used by an infected patient [51]. In med-
ical settings, EBOV RNA has been detected on many
environmental samples collected before cleaning in an Ebola
treatment center in Sierra Leone [75]. In contrast, 26 samples
collected inside or outside of the isolation wards after appropri-
ate disinfection during a SUDV outbreak in Gulu in 2000 [18],
16 samples in Madrid, Spain [33], and 14 samples collected in
Geneva, Switzerland (Kaiser, unpublished data), that were asso-
ciated with the West African outbreak all tested negative for
Ebola virus. The preponderance of data do not suggest that fo-
mites present a major public health problem in dedicated Ebola
treatment centers. However, data are still lacking regarding this
mode of contamination in overcrowded environments and
households lacking sanitation, in which various routes of trans-
mission may occur simultaneously. Indeed, Bower et al showed
that nearly half of the household members of EVD survivors
contracted the disease, with the risk of infection varying by
age and level of exposure, dropping from 83% for people touch-
ing a dead corpse to 8% for people with only minimal contact
with the infected initial case [92].
Role of Asymptomatic or Pauci-symptomatic Infections
Asymptomatic or mild infections with Ebola virus have been re-
ported on the basis of noted immune responses (IgM/IgG sero-
positivity) and RNA detection in contacts of infected patients
[44, 66, 68]. Preliminary results of the PREVAIL III study
being conducted in Liberia revealed that 49% of 97 close con-
tacts of survivors were IgG seropositive [36]. It is commonly ac-
cepted that, given the lack of symptoms, these people seem
unlikely to contribute significantly to human-to-human trans-
mission [44, 47]. One report relates a case of transmission of
SUDV from an asymptomatic person 2 days before develop-
ment of symptoms [46]. The case describe above of breastfeed-
ing transmission from an asymptomatic mother raises new
concerns about possibility of transmission from exposure to se-
lect body fluids of EVD survivors from which virus clearance is
delayed [39].
Other Risks of Transmission From Survivors
Virus shedding in the anterior chamber of the eye has been
shown to persist up to 14 weeks after onset of symptoms in a
survivor presenting with uveitis [32]. The presence of 5 muta-
tions in the viral sequence derived from the anterior chamber as
compared to the sequences obtained from the blood at the time
of viremia indicates viral replication and evolution through
multiple cycles and, thus, persistence of potentially infectious
virus. A concomitant conjunctival swab remained negative for
both EBOV RNA detection and virus isolation by cell culture,
suggesting that tears of survivors do not pose a transmission
risk. The infectious risk related to eye surgery in EVD survivors
remains to be determined.
Howlett et al reported having discharged a patient who was
still shedding viral RNA at low level in urine [34]. No secondary
transmission occurred within her contacts. Of note, her caregiv-
ers were aware of the test result and protected themselves while
Ebola Virus Shedding and Transmission • JID 2016:214 (Suppl 3) • S181
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/article-abstract/214/suppl_3/S177/2388183 by Acquisition Services user on 17 August 2019
handling her body fluids. Whether a positive RT-PCR result in
urine collected >1 month after a blood specimen tests negative
represents infectious virus or remnant viral RNA is still un-
known. Transmission through urinary contact of survivors,
however, seems unlikely and has not been reported, especially
if the survivor is ambulant and continent and can therefore
manage their own body fluids and secretions.
Recently, recrudescent EVD has been described [41], with
EBOV detected in the CSF of a survivor with EBOV meningo-
encephalitis 9 months after onset of disease. This report raises
new concerns about necessary infection control measures
while caring for survivors experiencing unexpected symp-
toms. However, noninvasive contact with Ebola survivors
without fever after remission seems to pose a negligible risk
of infection for HCWs; indeed, all specimens other than
semen (including blood, saliva, tears, sweat and skin swabs,
urine, vaginal secretions, and rectal swabs) tested negative
in 2 follow-up studies of survivors, conducted in 1995 in
the Democratic Republic of the Congo and in 2015 in Sierra
Leone [68, 93].
Implications on Discharge Policy
Incomplete knowledge concerning virus shedding patterns in
different body fluids also influences patient discharge strategies.
During the ongoing 2013–2016 EVD outbreak, a negative
RT-PCR result in blood was widely required to discharge a con-
valescent patient [94]. Clinically recovered patients who are
ambulatory and continent and who can manage their own
body fluids and secretions probably present a very low risk of
virus transmission, irrespective of the RT-PCR results. In his-
torical outbreaks, RT-PCR was not widely available, and yet
transmission from discharged patients has not been reported
to be an important source of disease.
CONCLUSION
Contact with body fluids from patients with EVD and cadavers
remains the major risk for transmission of Ebola virus, and ap-
propriate infection prevention and control measures are an ab-
solute necessity to protect HCWs in an EVD outbreak setting.
However, the relative infectivity of the various body fluids of pa-
tients with EVD remains to be established. While stools seem to
represent a major source of infection during acute disease, the
respective roles in Ebola virus transmission of saliva, vomitus,
and urine are not clear. Sexual transmission has been well doc-
umented, but the risk seems to remain low. The necessary infec-
tion prevention and control measures while caring for survivors
continue to be debated, especially regarding ophthalmologic or
urological procedures. Whether and how EBOV can persist in
protected body compartments other than semen, such as the
eye, CSF, or intra-articular fluid, and whether it can lead to
virus transmission remains unknown. Systematic data collection
and thorough laboratory investigations are still missing to fully
understand Ebola virus shedding and transmission.
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